Files in this item
Model-based relationship between the molecular bacterial load assay and time-to-positivity in liquid culture
Item metadata
dc.contributor.author | Svensson, Robin J | |
dc.contributor.author | Sabiiti, Wilber | |
dc.contributor.author | Kibiki, Gibson S | |
dc.contributor.author | Ntinginya, Nyanda E | |
dc.contributor.author | Bhatt, Nilesh | |
dc.contributor.author | Davies, Geraint | |
dc.contributor.author | Gillespie, Stephen H | |
dc.contributor.author | Simonsson, Ulrika S H | |
dc.date.accessioned | 2020-01-29T12:30:13Z | |
dc.date.available | 2020-01-29T12:30:13Z | |
dc.date.issued | 2019-10 | |
dc.identifier.citation | Svensson , R J , Sabiiti , W , Kibiki , G S , Ntinginya , N E , Bhatt , N , Davies , G , Gillespie , S H & Simonsson , U S H 2019 , ' Model-based relationship between the molecular bacterial load assay and time-to-positivity in liquid culture ' , Antimicrobial Agents and Chemotherapy , vol. 63 , no. 10 , e00652-19 . https://doi.org/10.1128/AAC.00652-19 | en |
dc.identifier.issn | 0066-4804 | |
dc.identifier.other | PURE: 260441860 | |
dc.identifier.other | PURE UUID: 1491e7cb-d5f0-4577-8220-365a1687fb62 | |
dc.identifier.other | PubMed: 31358585 | |
dc.identifier.other | ORCID: /0000-0001-6537-7712/work/60427409 | |
dc.identifier.other | ORCID: /0000-0002-4742-2791/work/60427618 | |
dc.identifier.other | Scopus: 85072609617 | |
dc.identifier.other | WOS: 000487320100053 | |
dc.identifier.uri | http://hdl.handle.net/10023/19374 | |
dc.description.abstract | The molecular bacterial load (MBL) assay is a new tuberculosis biomarker which provides results in ∼4 hours. The relationship between MBL and time-to-positivity (TTP) has not been thoroughly studied and predictive models do not exist. We aimed to develop a model for MBL and identify the MBL-TTP relationship in patients. The model was developed on data from 105 tuberculosis patients from Malawi, Mozambique and Tanzania with joint MBL and TTP observations quantified from patient sputum collected for 12 weeks. MBL was quantified using polymerase chain reaction (PCR) of mycobacterial RNA and TTP using the Mycobacterial Growth Indicator Tube (MGIT) 960 system. Treatment consisted of isoniazid, pyrazinamide and ethambutol in standard doses together with rifampicin 10 or 35 mg/kg. The developed MBL-TTP model included several linked sub-models; a component describing decline of bacterial load in sputum, another component describing growth in liquid culture and a hazard model translating bacterial growth into a TTP signal. Additional components for contaminated and negative TTP samples were included. Visual predictive checks performed using the developed model gave good description of the observed data. The model predicted greater total sample loss for TTP than MBL due to contamination and negative samples. The model detected an increase in bacterial killing for 35 versus 10 mg/kg rifampicin (p=0.002). In conclusion, a combined model for MBL and TTP was developed that described the MBL-TTP relationship. The full MBL-TTP model or each sub-model used separately. Secondly, the model can be used to predict biomarker response for MBL given TTP data or vice versa in historical or future trials. | |
dc.format.extent | 15 | |
dc.language.iso | eng | |
dc.relation.ispartof | Antimicrobial Agents and Chemotherapy | en |
dc.rights | © 2019 American Society of Microbiology. This work has been made available online in accordance with publisher policies or with permission from the rights holder. Permissions for further reuse of this content should be sought from the rights holder. This is the author created accepted manuscript following peer review and may differ slightly from the final published version. The published version should be used for citation purposes. The final published version of this work is available at https://doi.org/10.1128/AAC.00652-19 | en |
dc.subject | Tuberculosis | en |
dc.subject | Diagnostics | en |
dc.subject | Treatment monitoring | en |
dc.subject | Clinical trials | en |
dc.subject | QR180 Immunology | en |
dc.subject | RM Therapeutics. Pharmacology | en |
dc.subject | NDAS | en |
dc.subject.lcc | QR180 | en |
dc.subject.lcc | RM | en |
dc.title | Model-based relationship between the molecular bacterial load assay and time-to-positivity in liquid culture | en |
dc.type | Journal article | en |
dc.contributor.sponsor | Scottish Funding Council | en |
dc.description.version | Postprint | en |
dc.contributor.institution | University of St Andrews. School of Medicine | en |
dc.contributor.institution | University of St Andrews. Infection and Global Health Division | en |
dc.contributor.institution | University of St Andrews. Sir James Mackenzie Institute for Early Diagnosis | en |
dc.contributor.institution | University of St Andrews. Centre for Biophotonics | en |
dc.contributor.institution | University of St Andrews. Biomedical Sciences Research Complex | en |
dc.contributor.institution | University of St Andrews. Global Health Implementation Group | en |
dc.contributor.institution | University of St Andrews. Gillespie Group | en |
dc.contributor.institution | University of St Andrews. Infection Group | en |
dc.identifier.doi | https://doi.org/10.1128/AAC.00652-19 | |
dc.description.status | Peer reviewed | en |
dc.date.embargoedUntil | 2020-01-29 | |
dc.identifier.grantnumber | SFC/AN/10/2018 | en |
This item appears in the following Collection(s)
Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.